Armstrong, A J <br/><br/>
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.  [electronic resource] 

 -  Prostate cancer and prostatic diseases  Mar 2016 
 - 100-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5608 
<br/><br/><label>Standard No.: </label>10.1038/pcan.2015.59  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Disease-Free Survival<br/>Docetaxel<br/>Humans<br/>Indoles--administration & dosage<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Neoplasm Grading<br/>Neoplasm Recurrence, Local--drug therapy<br/>Prednisone--administration & dosage<br/>Prostate-Specific Antigen--metabolism<br/>Prostatectomy<br/>Prostatic Neoplasms--drug therapy<br/>Pyrroles--administration & dosage<br/>Quality of Life<br/>Salvage Therapy<br/>Sunitinib<br/>Taxoids--administration & dosage